Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules

文化大學機構典藏 CCUR > 理工學院 > 理學院 > 生命科學系 > 期刊論文 > Item 987654321/48823

請使用永久網址來引用或連結此文件: https://irlib.pccu.edu.tw/handle/987654321/48823

題名:	Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules
作者:	Ho, SY (Ho, Shu-Yi) Chen, PR (Chen, Pin-Rong) Chen, CH (Chen, Chia-Hung) Tsai, NM (Tsai, Nu-Man) Lin, YH (Lin, Yu-Hsin) Lin, CS (Lin, Chen-Si) Chuang, CH (Chuang, Cheng-Hsun) Huang, XF (Huang, Xiao-Fan) Chan, YL (Chan, Yi-Lin) Liu, YK (Liu, Yen-Ku) Chung, CH (Chung, Chen-Han) Weng, SL (Weng, Shun-Long) Liao, KW (Liao, Kuang-Wen)
貢獻者:	生科系
關鍵詞:	LPPC Gene therapy Anti-angiogenesis RBDV VEGFR
日期:	2020-04-09
上傳時間:	2020-11-12 09:55:00 (UTC+8)
摘要:	Background The anti-angiogenic fusion protein RBDV-IgG1 Fc (RBDV), which comprises the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A), has shown antitumour effects by reducing angiogenesis in vivo. This study used the cationic lipoplex lipo-PEG-PEI-complex (LPPC) to simultaneously encapsulate both the RBDV targeting protein and the RBDV plasmid (pRBDV) without covalent bonds to assess VEGFR targeting gene therapy in mice with melanoma in vivo. Results LPPC protected the therapeutic transgene from degradation by DNase, and the LPPC/RBDV complexes could specifically target VEGFR-positive B16-F10 cells both in vitro and in vivo. With or without RBDV protein-targeting direction, the pRBDV-expressing RBDV proteins were expressed and reached a maximal concentration on the 7th day in the sera after transfection in vivo and significantly elicited growth suppression against B16-F10 melanoma but not IgG1 control proteins. In particular, LPPC/pRBDV/RBDV treatment with the targeting molecules dramatically inhibited B16-F10 tumour growth in vivo to provide better therapeutic efficacy than the treatments with gene therapy with IgG1 protein targeting or administration of a protein drug with RBDV. Conclusions The simultaneous combination of the LPPC complex with pRBDV gene therapy and RBDV protein targeting might be a potential tool to conveniently administer targeted gene therapy for cancer therapy.
關聯:	JOURNAL OF NANOBIOTECHNOLOGY 卷冊: 18 期: 1 文獻號碼: 58
顯示於類別:	[生命科學系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	167	檢視/開啟

檢視Licence

在CCUR中所有的資料項目都受到原著作權保護.

資料載入中.....